Kendall Capital Management Sells 155 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Kendall Capital Management lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,965 shares of the company’s stock after selling 155 shares during the period. Kendall Capital Management’s holdings in Medpace were worth $985,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Pallas Capital Advisors LLC lifted its stake in Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares during the period. Baillie Gifford & Co. lifted its stake in Medpace by 175.6% during the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock worth $4,966,000 after purchasing an additional 9,478 shares during the period. Barclays PLC lifted its stake in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. CWA Asset Management Group LLC bought a new position in Medpace during the third quarter worth about $1,306,000. Finally, Oppenheimer Asset Management Inc. lifted its stake in Medpace by 6.3% during the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after purchasing an additional 2,675 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 2.2 %

NASDAQ MEDP opened at $332.81 on Friday. The firm has a market cap of $10.14 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 3.81 and a beta of 1.47. The company has a 50 day moving average of $341.10 and a 200-day moving average of $343.29. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.